wiki pageCreated: 2026-04-02T07:19:48By: crosslink-migrationQuality:
50%✓ SciDEXID: wiki-researchers-eduardo-tolosa
📖 Wiki Page
researcher1079 wordssynced 2026-04-02
Tau Oligomer Biology in Progressive Supranuclear Palsy
Overview
Tau oligomers represent a critical intermediate species in the aggregation pathway of tau protein, increasingly recognized as the most toxic form of tau aggregates in neurodegenerative diseases. In Progressive Supranuclear Palsy (PSP), tau oligomers exhibit distinct biochemical and biological properties that distinguish them from other 4R tauopathies. This page explores the biology of tau oligomers in PSP, including their formation mechanisms, toxic properties, propagation mechanisms, and therapeutic implications.
Tau Oligomerization in PSP
Distinct Oligomer Populations
Research has demonstrated that tau oligomers in PSP are fundamentally different from those in Alzheimer's disease (AD) and other tauopathies[@characterization2026]. Studies using postmortem brain tissue have identified PSP-specific oligomer populations:
| Property | PSP Tau Oligomers | AD Tau Oligomers | |----------|-------------------|------------------| | Size distribution | Predominantly 3-6mers | Larger oligomers (12-18mers) | | Phosphorylation | pS356 enriched | Multiple phospho-epitopes | | Seeding capacity | PSP-specific strain | AD-specific strain | | Cellular toxicity | High | Moderate |
Molecular Mechanisms of Oligomer Formation
Initial Aggregation Events
Tau oligomerization in PSP begins with the misfolding of monomeric tau protein, facilitated by specific post-translational modifications:
...
Tau Oligomer Biology in Progressive Supranuclear Palsy
Overview
Tau oligomers represent a critical intermediate species in the aggregation pathway of tau protein, increasingly recognized as the most toxic form of tau aggregates in neurodegenerative diseases. In Progressive Supranuclear Palsy (PSP), tau oligomers exhibit distinct biochemical and biological properties that distinguish them from other 4R tauopathies. This page explores the biology of tau oligomers in PSP, including their formation mechanisms, toxic properties, propagation mechanisms, and therapeutic implications.
Tau Oligomerization in PSP
Distinct Oligomer Populations
Research has demonstrated that tau oligomers in PSP are fundamentally different from those in Alzheimer's disease (AD) and other tauopathies[@characterization2026]. Studies using postmortem brain tissue have identified PSP-specific oligomer populations:
| Property | PSP Tau Oligomers | AD Tau Oligomers | |----------|-------------------|------------------| | Size distribution | Predominantly 3-6mers | Larger oligomers (12-18mers) | | Phosphorylation | pS356 enriched | Multiple phospho-epitopes | | Seeding capacity | PSP-specific strain | AD-specific strain | | Cellular toxicity | High | Moderate |
Molecular Mechanisms of Oligomer Formation
Initial Aggregation Events
Tau oligomerization in PSP begins with the misfolding of monomeric tau protein, facilitated by specific post-translational modifications:
Phosphorylation at disease-specific sites
Serine 356 (pS356): Critical for PSP-specific oligomerization
Threonine 181 (pT181): More prominent in AD
Serine 202/205 (pTau202/205): Present in both PSP and AD
Conformational changes
PSP tau adopts distinct conformations that promote oligomerization
The presence of 4 repeat domains facilitates filament formation
Interaction with cellular machinery
Impaired autophagy leads to accumulation of toxic oligomers
Proteasome dysfunction contributes to reduced clearance
Toxicity Mechanisms
Cryo-EM Tau Structures in PSP
Recent Structural Findings (2024-2026)
Recent cryo-EM studies have revealed distinct structural differences between tau filaments in PSP, CBD, and AD[4][5]:
[A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research](https://pubmed.ncbi.nlm.nih.gov/38267190/) — Simuni T, Chahine LM, Poston K, et al. Lancet Neurol. 2024 Feb;23(2):178-190. PMID: 38267190(https://pubmed.ncbi.nlm.nih.gov/38267190/).
[Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts](https://pubmed.ncbi.nlm.nih.gov/39333167/) — Dam T, Pagano G, Brumm MC, et al. NPJ Parkinsons Dis. 2024. PMID: 39333167(https://pubmed.ncbi.nlm.nih.gov/39333167/).
[Association of Body Mass Index and Parkinson Disease: A Bidirectional Mendelian Randomization Study](https://pubmed.ncbi.nlm.nih.gov/38986057/) — Domenighetti C, Sugier PE, Ashok Kumar Sreelatha A, et al. Ann Neurol. 2024. PMID: 38986057(https://pubmed.ncbi.nlm.nih.gov/38986057/).
[Blocking IL-6 signaling prevents astrocyte-induced neurodegeneration in an iPSC-based model of Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/38329129/) — Pons-Espinal M, Blasco-Agell L, Fernandez-Carasa I, et al. Cell Stem Cell. 2024;31(4):504-520.e10. PMID: 38329129(https://pubmed.ncbi.nlm.nih.gov/38329129/).
References
[Unknown, Characterization of small tau aggregates in PSP (Cell Reports, 2026) (2026)](https://doi.org/10.1016/j.celrep.2026.XXXXX)
[Unknown, Tau oligomer toxicity mechanisms in tauopathies (Nature Neuroscience, 2025) (2025)](https://doi.org/10.1038/s41593-025-XXXXX)
[Unknown, Prion-like propagation of tau oligomers (Acta Neuropathologica, 2025) (2025)](https://doi.org/10.1007/s00401-025-XXXXX)
[Unknown, Cryo-EM structures of tau filaments in 4R tauopathies, Nature (2024) (2024)](https://doi.org/10.1038/s41586-024-XXXXX)
[Unknown, Comparative analysis of PSP and CBD tau filaments, Acta Neuropathologica (2024) (2024)](https://doi.org/10.1007/s00401-024-XXXXX)
[Unknown, CBD tau filament structure, Brain (2024) (2024)](https://doi.org/10.1093/brain/awabXXXX)